esophageal cancer

Newly Public Lucid Diagnostics Posts $200K in Preliminary Q3 Revenues

The company's revenues were derived from its EsoGuard Esophageal DNA Test for esophageal cancer and related cell-collection device.

BTIG, Canaccord Genuity Initiate Coverage of Lucid Diagnostics With Buy Ratings

BTIG and Canaccord Genuity said Lucid's products have a total addressable market similar to that of Exact Sciences' Cologuard colorectal cancer screening test.

Castle Biosciences Buy of Cernostics Aligns With Goal to Diversify Portfolio
Premium

The acquisition of Cernostics and its TissueCypher Barrett's Esophagus Assay provides a route for Castle to enter gastrointestinal testing.

Agilent Obtains CE Mark for CDx to Guide Treatment With Immunotherapeutic Agent Opdivo

The CDx guides options for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal cancers.

Castle Biosciences Acquires Cernostics for up to $80M

Cernostics specializes in spatial biology and artificial intelligence-driven image analysis of tissue biopsies.

Oct 14, 2021

Lucid Diagnostics Prices $70M IPO, Starts Trading on Nasdaq

Jun 10, 2021

Lucid Diagnostics Obtains CE Mark for Esophageal Cancer Molecular Test

May 26, 2021

Lucid Diagnostics Gets CE Mark for Esophageal Cell Collection Device

Oct 12, 2020

Wales to Routinely Screen Cancer Patients With Yourgene Elucigene Test

Sep 24, 2020

Exact Sciences Stock Soars on New Data Around Pan-Cancer Liquid Biopsy Test

Sep 10, 2020

Cernostics, Deciphex to Collaborate on AI-Based Histology in Barrett's Esophagus

Aug 6, 2020

PavMed Raises $7M in Private Funding Round

Jul 1, 2020

AnchorDx Demonstrates Liquid Biopsy DNA Methylation Test for Early Cancer Detection

Apr 8, 2020